Results 61 to 70 of about 492 (136)

Embracing Uncertainties Over the Evidence of New Oral Antivirals for COVID‐19: Challenges in Pharmacoepidemiologic Research

, 2023
The Journal of Clinical Pharmacology, Volume 63, Issue 5, Page 521-525, May 2023.
Renato Ferreira da Silva, Ana Marta Silva, Manuela Morato, Inês Ribeiro‐Vaz, Jorge Junqueira Polónia   +4 more
wiley   +1 more source

Nifuroxazide Adverse Drug Reaction Characteristics and Descriptive Analysis From VigiAccess and EudraVigilance Databases [PDF]

Acta Poloniae Pharmaceutica - Drug Research
Nifuroxazide is a nitrofuran derivative with proven efficacy in the treatment of both acute and chronic bacterial diarrhea. The aim of this study is to assess the safety profile of nifuroxazide and to evaluate the occurrence of adverse drug reactions (ADRs).
Monika Birska, Karolina Kłosowska-Buryło, Grażyna Bodalska, Katarzyna - Karłowicz-Bodalska, Gabriela Jaryczewska   +4 more
openaire   +1 more source

Analysis of adverse event reporting patterns following COVID-19 vaccination: findings from VigiAccess, FAERS and EudraVigilance databases with comparative assessment of data representation and categorization across three databases [PDF]

The clinical presentation of COVID-19 varied from mild to severe or fatal illness, and vaccination played a pivotal role in preventing the spread of severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2). Despite cumulative evidence suggesting that
Bhave, Kiran A., Pandit, Prasad R., Mahurkar, Ram N., Patel, Tejal C.   +3 more
core   +1 more source

Increased Libido Following Brivaracetam Initiation: A Case Report of Temporal Lobe Epilepsy

Neuropsychopharmacology Reports, Volume 46, Issue 3, September 2026.
This case report highlights a patient with temporal lobe epilepsy who experienced a distressing libido increase following brivaracetam initiation. Although primarily associated with brivaracetam, incomplete Klüver–Bucy syndrome and concurrent brexpiprazole may have also been involved.
Toru Horinouchi, Taiki Matsuyama, Mayusa Mito, Yuichi Nakamura, Takahiro A. Kato   +4 more
wiley   +1 more source

The Role of Pharmacovigilance Database in Identifying Antibiotic Resistance and Inappropriate Use: An Analysis of VigiBase Reports From Lower‐Middle‐Income Countries

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Background Digital databases such as pharmacovigilance (PV) databases could provide unique opportunities to monitor trends in suspected antibiotic resistance, ineffectiveness, and misuse, extending beyond their traditional role of tracking adverse drug reactions (ADRs).
Hager Saleh, Joseph Mitchell, Cecilia Stålsby Lundborg, Megha Sharma   +3 more
wiley   +1 more source

Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data

Headache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1128-1147, May 2026.
Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Martina Giacon, Salvatore Terrazzino
wiley   +1 more source

Integrating gepants into clinical practice for the acute treatment of migraine

Headache: The Journal of Head and Face Pain, Volume 66, Issue 4, Page 976-989, April 2026.
Abstract Objective To assess the role of small‐molecule calcitonin gene–related peptide receptor antagonists (gepants) in the acute treatment of migraine, particularly in relation to triptan treatments. Background Triptans have established efficacy and are widely prescribed for the acute treatment of migraine.
Richard B. Lipton, David W. Dodick, Linda Davis, Stephanie J. Nahas, Peter J. Goadsby   +4 more
wiley   +1 more source

Case Report: Omadacycline in the Treatment of Community‐Acquired Pneumonia in a Child With Multiple Antimicrobial Allergies

Clinical Case Reports, Volume 13, Issue 12, December 2025.
ABSTRACT Omadacycline, a novel once‐daily aminomethylcycline antibiotic agent, demonstrates efficacy against prevalent pathogens responsible for community‐acquired pneumonia (CAP) in adults. However, the safety and efficacy of omadacycline in younger children have not yet been established.
Ziqi Xu, Wen Pan, Hui Lei, Chen Dong, Biao Zou, Sainan Shu, Wenting Zhang   +6 more
wiley   +1 more source

Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper

Allergy, Volume 80, Issue 11, Page 2973-2987, November 2025.
ABSTRACT Antiplatelet drug (APD) therapy is the cornerstone for the prevention of atherosclerotic cardiovascular disease. The main APDs are aspirin and thienopyridines, particularly clopidogrel. These drugs may induce hypersensitivity reactions (HSRs).
Gabriele Cortellini, Alla Nakonechna, Annick Barbaud, Sevim Bavbek, Gianfranco Calogiuri, Inmaculada Doña, Violeta Kvedariene, Jose Julio Laguna Martinez, Serena Liberati, Mauro Pagani, Antonino Romano   +10 more
wiley   +1 more source

Serious Adverse Events: A Replicability and Validation Study of Naranjo Causality Assessment Tool in a Canadian Clinical Setting

Journal of Evaluation in Clinical Practice, Volume 31, Issue 3, April 2025.
ABSTRACT Rationale Patient safety has become a major concern in healthcare today as 5%–10% of patients experience serious adverse events (SAE) during their hospital stay. The causal assessment of SAE is the responsibility of healthcare professionals (HCP), who use their judgment or a standardize tool. Whether those two methods are replicable to provide
Pallavi Pradhan, Sonia Corbin, Shweta Todkar, Maude Lavallée, Isabelle Cloutier, Rosalie Darveau, Julie Méthot, Anick Bérard, Marie‐Eve Piché, Jacinthe Leclerc   +9 more
wiley   +1 more source